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Sarcomas are highly aggressive heterogeneous tumors that are mesenchymal in origin.
There have been vast advancements on identifying diagnostic markers for sarcomas
including chromosomal translocations, but very little progress has been made to identify
targeted therapies against them. The tumor heterogeneity, genetic complexity and the
lack of drug studies make it challenging to recognize the potential targets and also
accounts for the inadequate treatments in sarcomas. In recent years, microRNAs that are
a part of small non-coding RNAs have shown promising results as potential diagnostic
and prognostic biomarkers in multiple sarcoma types. This review focuses on the current
knowledge of the microRNAs that are deregulated in sarcomas, and an insight on the
strategies to target these microRNAs that are essential for developing improved therapies
for various human sarcomas.
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Introduction
Sarcomas are malignant tumors that are mesenchymal in origin (Taylor et al., 2011a). They are
rare, highly complex heterogeneous tumors accounting for about 1% of all other tumor types in
humans. They are of particular importance to pediatrics as 15% of all pediatric malignant tumors
are sarcomas. Sarcomas are known to occur in different body parts and based on the cell/tissue type
can be broadly identified as bone or soft tissue sarcomas and further classified into more than 50
subtypes (Weiss et al., 2007). Additionally, there is another set of classifications that are based on
the genetic alterations (Stephens et al., 2011). The first category is based on genetic alterations that
include translocations or specific mutations. Most of the sarcomas fall under this first category.
However there are some sarcomas such as leiomyosarcoma and osteosarcoma, that fall into a
second category that present complex karyotypes with multiple genomic instabilities.
The general standard of care for most sarcoma types consists of surgical resection and
chemotherapy. This method yields poor responses and the majority of cases succumb due to lung
metastasis. Despite the advancements in diagnosis and prognosis of the disease, treatment options
have remained stagnant for the past three decades. Potential reasons for this include rarity of tumor
incidence, genetic complexity, and late stage at diagnosis leading to poor prognosis. All the above
reasons lead to an urgent need to identify novel biomarkers that are targetable, which will eventually
lead to better diagnosis and prognosis of sarcomas.
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MicroRNAs (miRNAs) have a crucial role in predicting the
disease outcome and the prognosis in various cancer types
including sarcoma (Calin et al., 2008; Cuiffo et al., 2014).
miRNAs are a group of small non-coding RNAs that regulate
genes post transcriptionally. Over the past few years, various
miRNA deregulations have been accounted an aid in histological
classification and clinical relevance of sarcomas. To address the
role of miRNAs in various sarcomas, this review will highlight
how various miRNAs play crucial roles in human sarcomas
and an insight on current miRNA target based therapeutic
approaches.
Bone Sarcomas
Bones sarcoma consists of only 0.2% of all the neoplasms. Major
known bone sarcomas include osteosarcoma, chondrosarcoma,
and Ewing sarcoma (Burningham et al., 2012). The sub-
classification of these bone sarcomas is based on their histology,
cell of origin and the tissue site. We will discuss each of the bone
sarcomas below.
Osteosarcoma
Osteosarcoma is the most common primary malignant bone
tumor and primarily occurs in adolescents. The incidence rate of
osteosarcoma is approximately 4–5 cases per million (Mirabello
et al., 2009). It usually arises from the metaphysis of the
long bones such as the femur. Studies, including ours, have
shown that miRNAs deregulation occurs in osteosarcoma (Maire
et al., 2011; Thayanithy et al., 2012). We observed that there
is a significant downregulation of around 50 miRNAs at the
chromosome 14q32 locus (14q32 miRNAs) in osteosarcoma
compared to the normal bone without any alterations in the
copy number changes at the locus (Thayanithy et al., 2012). This
suggests that there might be additional epigenetic changes in
that region. The bioinformatics predictions identified a subset
of these 50 miRNAs (miR-382, miR-369-5p, miR-544, and miR-
134) that could potentially target the 3′UTR of the cMYC
transcript (Thayanithy et al., 2012). Upon functional validation,
we found that restoring the expression of the four 14q32
miRNAs decrease the cMYC levels and induced apoptosis in
osteosarcoma cell lines (Saos2). In the same set of cell lines the
14q32 miRNAs overexpression led to significant decrease in an
oncogenic miRNA cluster called miR-17-92, which also happens
to be a transcriptional target of cMYC (Olive et al., 2010). We
also performed rescue experiments where we both overexpressed
cMYC in absence of its 3′UTR, or the miR-17-92 cluster and
found that osteosarcoma cells could be rescued from the pro-
apoptotic effects of the 14q32 miRNAs. In total, we observed that
there is a deregulation that involves 14q32 miRNAs, cMYC and
miR-17-92, which could contribute to osteosarcoma progression
(Maire et al., 2011; Thayanithy et al., 2012). Maire et al. also
found that there is deregulation of miRNAs that could target
multiple signaling pathways such as MAPK, Wnt and RAS/p21
that played a crucial role in osteosarcoma. In order to find
the relationship between various miRNAs and pathways, they
generated a comprehensive genetic map that integrated miRNAs
and gene expression profiles obtained from various osteosarcoma
tumor samples. The mentioned authors, in concurrence with
our observation, found the deregulation in miR-382 and cMYC
levels in osteosarcoma, further suggesting the role of miRNAs in
osteosarcoma progression.
There are several other groups that have contributed in
understanding the role of miRNAs in osteosarcoma (Duan et al.,
2011; Lulla et al., 2011; Jones et al., 2012). Braun et al. found
that miRNAs such as miR-192 and miR-215 are p53 responsive
miRNAs that are capable of causing cell cycle arrest in the
osteosarcoma cell line U2OS that carries a wild-type p53 (Braun
et al., 2008). Other groups have also shown that miRNAs such as
miR-34a and miR-31 could arrest proliferation in osteosarcoma
cell lines in association with p53 (Creighton et al., 2010; Yan et al.,
2012). miR-31 was also shown to target multiple metastatic genes
such as integrin A5, radixin, and RhoA indicating its potential
role in the prevention of metastasis in osteosarcoma (Creighton
et al., 2010).
There are several studies that showed that miRNAsmight have
a potential therapeutic role in osteosarcoma as well. For instance
Duan et al. found that miR-199a-3p restoration decreased mTOR
and Signal Transducer and Activator of Transcription (STAT)
expression and proliferation and migration in osteosarcoma cells
making it a strong therapeutic candidate in osteosarcoma (Duan
et al., 2011). Similar results were obtained with knock down
of miR-21 that is usually overexpressed in osteosarcoma, which
targets RECK and affects the activation of MMPs (Kang et al.,
2007; Ziyan et al., 2011). Another miRNA, miR-183 targets
Ezrin that leads to suppression of migration and invasion in
osteosarcoma cells. Further, it has been shown that miR-183
correlates with pulmonary metastasis and local recurrence of
osteosarcoma, suggesting its crucial role in metastasis (Zhu et al.,
2012).
miRNAs have also been shown to be useful as biomarkers
of chemotherapeutic responses in osteosarcoma. Some of the
first known miRNAs that have been associated with drug
sensitivity are miR-140 and miR-215 (Song et al., 2009, 2010; Zhu
et al., 2012). The studies revealed that miR-140 overexpression
led to chemoresistance to various chemotherapeutics such as
methotrexate (MTX) and 5- fluorouracil (5-FU). Also, miR-140
negatively regulated histone deacetylase 4 (HDAC 4) resulting
in 5-FU resistance. Similarly, miR-215 induced chemoresistance
to MTX in U2OS cells. Another study examined the miRNA
expression of 27 paraffin embedded osteosarcoma samples to
determine chemoresistance to ifosfamide (IFO) (Gougelet et al.,
2011). They performed supervised hierarchical clustering and
found five miRNAs, miR-92a, miR-99b, miR-132, miR-193-
5p, and miR-422 that could significantly differentiate between
good and poor responders to IFO. A recent study by Lauvrak
et al. evaluated miRNAs in 22 osoteosarcoma cell lines that
are crucial for various cellular functions including proliferation,
invasion, and migration (Lauvrak et al., 2013). They found
that miR-199b-5p and miR-100-3p were downregulated and
miR-155-5p, miR-135-5p, and miR-146-5p upregulated in more
aggressive osteosarcoma cell lines. Further studies would be
required to correlate these miRNAs with genes that regulate
tumor growth andmetastasis in osteosarcoma. Thus, such studies
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unveil the multiple roles of miRNAs in prognosis, diagnosis,
therapeutics, and drug resistance in osteosarcoma and other
sarcomas.
Ewing Sarcoma
Ewing sarcoma is a pediatric sarcoma that usually originates in
bone. The most common genetic alteration is transcript fusion
of transcription regulators EWS and Ets leading to a novel
transcriptional factor that drives oncogenesis. Two independent
studies revealed global miRNA expression changes due to stable
repression of fusion proteins in Ewing sarcoma (Ban et al.,
2011; McKinsey et al., 2011; Dylla et al., 2013). The miRNAs
predicted in one of these studies showed that these miRNAs
could potentially target insulin-like growth factor (IGF), which
is a crucial driver of Ewing sarcomagenesis (McKinsey et al.,
2011). The other study identified miR-145 as a top candidate
miRNA that is repressed in Ewing sarcoma (Ban et al., 2011).
Interestingly, miR-145 could directly target the EWS/Fli1 fusion
transcript and this regulatory network should be explored further
as a potential miRNA-mediated therapy in this type of cancer.
Let-7a is another miRNA that was identified as a direct target
toward the fusion transcript (De Vito et al., 2011).
Other studies involved investigating the role of miRNAs
as biomarkers in Ewing’s sarcoma (Mosakhani et al., 2012;
Nakatani et al., 2012). One of the groups showed that patients
with high levels of miR-34a had better 5-year survival outcome
than patients with low levels of miR-34a (Nakatani et al.,
2012). In an integrated analysis study of miRNAs and copy
number changes revealed around 20 differentially expressed
miRNAs in chromosomal regions with altered copy numbers
(Mosakhani et al., 2012). A recent study identified 35 miRNAs
that were differentially expressed in Ewing sarcoma tissues and
cell lines compared to the mesenchymal stem cells (Karnuth
et al., 2014). They identified miR-31 as a potential tumor
suppressor that affected proliferation and invasion in Ewing cell
lines. Interestingly, the group found no significant differentially
expressed miRNAs that could possibly distinguish between
Ewing sarcoma samples that were from primary and metastatic
group.
Chondrosarcoma
Chondrosarcoma is a rare malignant tumor arising
from transformed cartilaginous cells. This happens when
osteochondromas transform into chondrosarcoma and usually
occurs in 1–5% of patients. Several studies have shown
involvement of miRNAs in chondrogenesis and cartilage based
diseases (Tuddenham et al., 2006; Lin et al., 2009; Zhang et al.,
2013). One study shows that there are eight miRNAs that are
deregulated in osteochondroma patients compared to normal
subjects (Zuntini et al., 2010). These miRNAs were further
shown to regulate genes that are involved in normal growth plate
formation that includes heparin sulfate and glycan structure
biosynthesis. Hameetman et al. identified a similar differential
miRNA profile in chondrosarcoma patients indicating
the miRNAs involvement in osteochondroma malignant
transformation to chondrosarcoma (Hameetman et al., 2006).
The first significant study of miRNAs in chondrosarcoma
tissue samples and cell lines revealed downregulation of let-7a,
miR-100, miR-136, miR-222, miR-335, and miR-376a compared
to normal chondrocytes (Yoshitaka et al., 2013; Nugent, 2014).
Another recent study shows that overexpressing proline-rich
polypeptide (PRP-1) inhibited mTORC1, which resulted in
upregulation of certain tumor suppressor miRNAs (miR-125b,
miR-192) and downregulation of oncomiRs (miR-550, miR-589,
miR-490-3p) (Galoian et al., 2014). Similarly, another study
demonstrated that overexpression of miR-518b decreased
the expression of Bcl-2, which is an anti-apoptotic that led
to increased expression of Bax, a pro-apoptotic in human
chondrosarcoma cell lines (Liang et al., 2014). The above studies
indicate that miRNAs are crucial players in chondrosarcoma and
further functional validation should be performed to confirm
their role.
Soft Tissue Sarcomas
Sarcomas that affect connective tissues such as muscle, fat, and
blood vessels fall under the soft tissue sarcomas. Such sarcomas
account for approximately 1% of all malignant tumors. We will
discuss the commonly known soft tissue sarcomas in the section
below.
Gastrointestinal Stromal Tumor
Gastrointestinal stromal tumor (GIST) is considered the most
common tumor of mesenchymal origin arising from interstitial
cells of Cajal in the gastrointestinal tract. Most of them have
C-KIT or PDGFRA mutations. We found lower levels of miR-
221 and miR-222 that target 3′UTR of KIT leading to KIT gene
overexpression, enhancing the oncogenicity of the GIST cells
(Subramanian et al., 2008). Another group consistently found
lower levels of miR-221 and miR-222 in KIT- positive GISTs
compared to normal tissues, suggesting that these miRNAs have
a therapeutic potential in KIT-positive GISTs (Felli et al., 2005).
Another miRNA, miR-494, which is a negative regulator of KIT
has been shown to be significantly low in GISTs which indicates a
promising therapeutic target in GISTs (Kim et al., 2011).
Two separate research studies found that there is a significant
downregulation of ∼44 miRNAs in human chromosome
14q32 region in 12 GIST samples (Haller et al., 2010; Kelly
et al., 2013). Moreover, they observed these miRNAs were
inversely correlated with GIST tumor progression indicating
their prognostic significance. Another group found a lower level
of miR-196, which is one of the miRNAs from the human
14q32 chromosomal region that was associated with metastasis
and poor survival outcomes (Choi et al., 2010). Thus, these
studies indicate the crucial role of miRNAs in diagnostics and
therapeutics in GIST patients.
Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a skeletal muscle-derived
malignant sarcoma. RMS affects approximately 6–8% of
Frontiers in Molecular Biosciences | www.frontiersin.org 3 June 2015 | Volume 2 | Article 31
Varshney and Subramanian MicroRNAs in sarcoma therapeutics
pediatric cases. RMS can be classified into two main subtypes,
embyonal RMS (ERMS), and alveolar RMS (ARMS) (Weiss
et al., 2007). ARMS is considered more aggressive and has poorer
outcomes compared to ERMS (Qualman et al., 1998). ARMS
is also associated with various chromosomal translocations
that result in an oncogenic fusion protein. A common fusion
transcript in ARMS is PAX3-FKHR. The role of miRNAs in RMS
is more studied in relation to myomiRs as these sarcomas are
thought to originate from myogenic precursors (Subramanian
et al., 2008). miRNAs such as the miR-1/ -133/ -206 family are
known to specifically regulate myogenic differentiation and
muscle tissue homeostasis. Such myomiRs form an attractive
area to study for therapeutics in RMS.
Our group and others have shown that miRNA expression
profiling is a good tool to determine the differences between
ERMS and ARMS (Subramanian et al., 2008). For instance
myomiRs are significantly downregulated in RMS and gain-
of-function experiments demonstrated that overexpression of
the myomiRs would inhibit RMS proliferation suggesting their
tumor suppressive role in RMS. We showed that miR-1 and miR-
206 were significantly downregulated that led to stabilization
of PAX3 and cyclin D2 in RMS. In ARMS, PAX3 fuses with
FKHR that leads to the loss of 3′UTR of PAX3 leading to its
oncogenic mechanism in ARMS. Further experiments revealed
that overexpression myomiRs such as miR-206 accelerated
myogenic differentiation and prevented tumor growth in a
xenograft mouse model (Taulli et al., 2009; Yan et al., 2009). The
other myomiR, miR-335, is overexpressed in ARMS (Yan et al.,
2003). miR-335 is located within intron 2 of PEG1 that plays
a role in muscle differentiation. PEG1 is a known downstream
target of PAX3 and it is likely that the PAX3-FKHR fusion in
ARMS might influence the transcription of PEG1 and miR-335
in ARMS. Another study aimed to identify miRNAs that are
responsible for metastasis in ARMS (Armeanu-Ebinger et al.,
2012). They found thatmiR-9, which is associated withmetastasis
and invasion, is overexpressed in ARMS. On the contrary miR-
200c that inhibits migration was downregulated in ARMS. This
suggests that miRNAs could be responsible for metastasis and
should be explored further as therapeutic targets in ARMS.
There are several other miRNAs that are not myomiRs, which
are affected in RMS. miR-29 levels are significantly low in RMS
and re-expression leads to cell cycle arrest and differentiation in
RMS cell lines (Weiss et al., 2007). Wang et al. demonstrated
that there is activation of NF-κb in RMS, which leads to
overexpression of transcription factor YY1 (Wang et al., 2008).
The overexpression of YY1 leads to interaction with its cofactor
EZH2 leading to downregulation of miR-29b/c in RMS cell lines
and tumor tissues. Additionally, miR-29 targets E2F7, which is
a crucial cell cycle regulator. Ectopic expression of miR-29 leads
to G1 arrest and cell death. Not only does miR-29 regulate cell
cycle,it has also been implicated to target HDAC4 and affect
epigenetic regulation (Li et al., 2009). miR-183 is another non-
myomiR miRNA that plays an oncogenic role in RMS (Sarver
et al., 2010a). miR-183 overexpression leads to repression of
EGR1 which is a known tumor suppressor and a transcription
factor (Sarver et al., 2010a). Low levels of EGR1 affect the levels of
transcriptional target PTEN. Thus, miR-183 levels play a crucial
role in balancing the levels of two major tumor suppressor genes.
These studies demonstrate that myomiRs and non-myomiRs play
a major role in RMS and further research should be focused
on therapeutics that can correct such miRNA deregulation
in RMS.
Malignant Peripheral Nerve Sheath Tumor
Malignant peripheral nerve sheath tumors (MPNSTs) are
soft tissue sarcoma tumors that occur in patients with
neurofibromatosis type 1 disease. Our group identified p53
inactivation in most of the MPNST patients via a genome-
wide transcriptome analysis (Subramanian et al., 2010). In
the same study we performed miRNA profiling of benign
and malignant PNSTs samples that revealed miR-34a being
downregulated in most of the MPNSTs samples compared
to benign neurofibromas. Also, we found that miR-214 was
upregulated in MPNSTs, which is a direct transcriptional target
of metastatic gene TWIST1 (Yang et al., 2004; Lee et al.,
2009). miR-214 was also shown to target PTEN, indicating
a deregulation in the TWIST1-miR-214-PTEN pathway in
MPNSTs. Another group reported miR-10b upregulation in
MPNST tumors and cell lines (Chai et al., 2010). They further
performed functional validation by inhibiting miR-10b that led
to decrease in cell proliferation, migration, and invasion in
MPNST cell lines. They revealed that miR-10b inhibition affected
Ras signaling and NF1 expression leading to cellular arrest.
miR-21 was also shown to target a neoplastic transformation
inhibitor, PDCD4, that led to MPNST tumor formation and
progression (Itani et al., 2012). Interestingly, miR-21 was found
to be over expressed in schwannomas, which are benign
tumors consisting of NF2 mutations. However, upon gene
and miRNA profiling of various schwannomas, neurofibromas
and MPNST samples, it was found that both miRNAs and
various genes associated with neurofibromas and schwannomas
clustered separately compared to MPNSTs, indicating that
miRNAs could be useful tool to diagnose and stratify MPNSTs
from neurofibromas and schwannomas (Subramanian et al.,
2010). Recently, a study showed 16 differentially expressed
miRNAs in neurofibromas and MPNSTs from patients with
NF1 via microarray analysis (Presneau et al., 2013). Of the 16
differentially expressed miRNAs, 14 were downregulated and 2
miRNAs (miR-210 and miR-339-5p) were upregulated. These
miRNAs were further validated by qPCR and overexpression
experiments using miRNAmimics in the MPNST cell lines. Also,
one of the dowregulated miRNAs, miR-29c was predicted to
target various genes including MMP-2 that are responsible for
invasion and metastasis. This demonstrated that overexpression
of miR-29c reduced invasion in MPNST cell lines, indicating that
certain miRNA levels could be manipulated to reduce metastasis
in MPNSTs.
Synovial Sarcoma
Synovial sarcoma (SS) is an adolescent sarcoma originating near
the joints and represents around 8% of all soft tissue sarcomas.
We were the first group to examine miRNA expression profiles
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in synovial sarcoma (Subramanian et al., 2008). We found that
miR-143 levels were significantly low in SS compared to other
soft tissue sarcomas such as GIST and LMS and miR-143 targets
ERK5 or MAPK7. EKR5 plays a crucial role in cellular growth
and proliferation via tyrosine kinase signaling, and lower levels
of miR-143 leads to amplified ERK5 levels leading to SS (Esau
et al., 2004). miR-143 is also known to target a common fusion
transcript; SS18-SSX1 in SS. Our group revealed that miR-
183 is a potential oncomiR in SS (Sarver et al., 2010a). The
reason is miR-183 is overexpressed in SS and it targets two
important tumor suppressor genes, EGR1 and PTEN, leading to
their repression and increase cell proliferation. Hisaoka et al.
performed global miRNA expression profiles and found that
there are 35 miRNAs, which are differentially expressed in SS
compared to other sarcomas (Hisaoka et al., 2011). Let-7e,
miR-99b and miR-125a-3p were highly upregulated in SS and
arise from the same chromosomal loci. These miRNAs targeted
HMGA2 and SMARCA5 that led to cellular proliferation. Such
miRNA differential studies and further functional validation will
aid in better understanding of miRNAs as a diagnostic and
therapeutic potential in synovial sarcomas.
Leiomyosarcoma
Leiomyosarcoma (LMS) is a sarcoma of uterine smooth muscle.
We performed a microarray analysis of LMS and normal smooth
muscle samples and found that miRNAs such as miR-1 and miR-
133a/b, which are regulators of myogenesis, were significantly
overexpressed in LMS (Chen et al., 2006; Subramanian et al.,
2008). Another group showed that there are more than 70
miRNAs that are differentially expressed including miR-17-92 in
LMS compared to normal uterine smooth muscles (Danielson
et al., 2010). Shi et al. demonstrated the association between let-
7 and its target HMGA2 (Shi et al., 2009). They functionally
validated that lower levels of let-7 leads to overexpression of
HMGA2 in LMS.
miRNAs role was also investigated as potential diagnostic
biomarkers in LMS. A group found that miR-221 levels
could differentiate between LMS from their benign counterpart
(leiomyoma) (Nuovo and Schmittgen, 2008). Another miRNA,
miR-21 was differentially expressed in leiomyoma compared
to LMS (Nuovo and Schmittgen, 2008). They demonstrated
that miR-21 was and hormonally deregulated in leiomyomas.
In addition to this study, Guled et al. demonstrated miRNAs
including miR-199b-5p, miR-320a, miR-199a-3p, miR-126, and
miR-22 were differentially expressed in LMS and undifferentiated
pleomorphic sarcoma (UPS) as compared to mesenchymal stem
cells (control) (Guled et al., 2014). These miRNAs indicate their
importance in diagnosing and differentiating between LMS and
UPS. Thus, further studies must be undertaken to functionally
validate the miRNAs to confirm their clinical importance as
diagnostic markers.
Liposarcoma
Liposarcoma originates from fat cells and is the most common
mesenchymal cancer. One of the miRNA studies was comprised
of identifying miRNAs in liposarcomagenesis (Ugras et al.,
2011). They performed small RNA sequencing between well-
differentiated liposarcoma, dedifferentiated liposarcoma and
normal adipose tissue samples. Such analysis revealed over 40
miRNAs including miR-21 and miR-26a, to be upregulated and
miR-143 and miR-145 to be downregulated in dedifferentiated
liposarcomas as compared to normal adipose tissue. They
performed functional validation of miR-143 as a tumor
suppressor as it represses expression of BCL2, topoisomerase
2A and PLK1 leading to cellular arrest. Similar independent
studies revealed that miR-155 was overexpressed and miR-193b
was downregulated in dedifferentiated liposarcoma as compared
to their differentiated counterpart (Taylor et al., 2011b; Zhang
et al., 2012). miR-155 targeted casein kinase 1 alpha that
increased expression of beta-catenin signaling and cyclin D1,
inducing cell growth and tumorigenesis (Zhang et al., 2012).
The other study performed sequencing of genome, exome and
transcriptome and found that miR-193b helps in distinguishing
differentiated vs. dedifferentiated liposarcomas (Taylor et al.,
2011b). Recently, a study demonstrated miR-143/145 and
miR-144/451 cluster members were significantly downregulated
in liposarcoma compared to adipocytes indicating their
potential role as tumor suppressors (Gits et al., 2014). Over-
expression of the clusters was able to significantly reduce
proliferation and induce apoptosis in liposarcoma cell lines
and hence these miRNAs can aid in diagnosis of liposarcoma
patients.
Other Sarcoma Types
There are other soft tissue sarcomas that are quite rare and
understudied in relation to miRNAs.
Fibrosarcoma is derived from fibrous connective tissue.
There are few studies that have investigated role of miRNAs
in fibrosarcoma. miR-520c and miR-373 have been shown
to activate Ras/MAPK pathway via activation of MMP9 in
fibrosarcoma cell lines (Liu and Wilson, 2012). Another study
revealed a potential tumor suppressor miRNA, miR-409-3p that
downregulated angiogenin expression levels leading to cell death
and tumor regression (Weng et al., 2012).
Angiosarcoma is another type of soft tissue sarcoma and our
study identified miRNAs such as miR-552, −519, −515, −517a
are upregulated in angiosarcomas as compared to other sarcomas
(Sarver et al., 2010b). Further functional validation of these
miRNAs will be required.
The other understudied soft tissue sarcoma in relation
to miRNAs is hemangiosarcoma. There is only one study
that demonstrates upregulation of miR-17-92 cluster in MYC-
amplified hemangiosarcoma compared to hemangiosarcoma
with no MYC amplification (Italiano et al., 2012). This
implies that miR-17-92 overexpression is dependent on MYC
amplification in this type of sarcoma. Also, upregulation of miR-
17-92 decreased thrombospondin-1 (THBS1) expression that
enhanced angiogenesis, indicating a MYC-miR-17-92 dependent
pathogenesis in the MYC-amplified hemangiosarcoma tumor
tissues.
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miRNA Therapeutics - an Insight on the
Future for Sarcomas
We have known about miRNAs and their role in mRNA
regulation for over a decade; however, we still do not entirely
understand the molecular mechanisms of how miRNAs regulate
gene expression nor have we identified and established all the
miRNA targets in the human genome (Fabbri et al., 2011). Thus,
it becomes essential to understand the function and targets of
miRNA by inhibiting the miRNA in a biological process. Such
functional studies will also aid in targeting miRNAs that are
deregulated in various sarcomas. To help understand the role of
miRNAs in potential therapeutics, two strategies are commonly
used: (i) direct cellular delivery of chemically synthesized miRNA
inhibitors [such as antisense oligonucleotides (ASOs)] and (ii)
delivery of a vector from which intracellular transcription of
RNA inhibitors occurs (miRNA sponges or decoys) (Figure 1)
(Li, 2014).
ASOs are short, single stranded DNA or RNA sequences
that can specifically inhibit miRNAs (Dias and Stein, 2002).
The mechanism of inhibition by ASOs is via Watson-Crick
base pairing. The first ASOs were introduced via lipid-mediated
transfection in C. elegans (Faltus et al., 2004; Zheng et al., 2010).
Antagomirs or modified ASOs were the first miRNA inhibitors
used in mammals (Krutzfeldt et al., 2005). Antagomirs contain
a 2′-O-methyl modified ribose sugars terminal phosphorothiates
and a cholesterol group at the 3′ end. The cholesterol group
enhances the cellular uptake of the antagomirs due to their
binding affinity to the cell surface membrane receptors. The
challenge with antagomirs as a clinical application is that they
require a higher dose to reach a certain efficacy as compared to
other modified ASOs described below.
With the advancement in RNA chemistry, locked nucleic
acid (LNA) was synthesized that has enhanced binding affinity
toward miRNAs as compared to modified ASOs (Davis et al.,
2006; Esau et al., 2006; Zheng et al., 2010). LNAs have 2′-
4′-methylene bridge that locks the sugar ring in the 3′ endo
conformation (Kumar et al., 1998). Such conformation along
with addition of other modifications led to better affinity and
stability of these ASOs in vivo. Subsequently, LNAmodifications’
application showed that it increased melting temperature and
specificity in targeting miRNAs. The first known LNA-modified
oligo was used to inhibit miR-122 that lowered plasma cholesterol
levels in African green monkeys (Elmen et al., 2008). This non-
human primate study showed that such oligonucleotides were
specific, stable and non-toxic when administered intravenously
for a prolonged period. Following this study, another group
showed that there was inhibition of HCV replication via LNA
that inhibited miR-122 in chimpanzees (Lanford et al., 2010).
Interestingly, no viral escape was observed in the chimpanzees
that were injected with LNA after 16 weeks, which was not
obtained with antiviral therapy. After successful trials on non-
human primates, LNAs against miR-122 are being tested in
humans (Orom et al., 2006; Elmen et al., 2008). There has been
a successful phase 1 trial that has paved its way to phase 2 study
in human patients with chronic HCV infection (http://www.
santaris.com).
As of today, such success has primarily been observed in
liver infections. The reason is that the liver is amongst the most
successful organs in the uptake of therapeutic RNAs. Not only is
the bioavailability a challenge, but also there are other hurdles
in therapeutic delivery of such RNAs that include size of the
RNA and mode of delivery (Fabbri et al., 2011). Any RNAs
less than 50 kDa are filtered through the kidney and excreted
so local delivery of the modified RNAs is preferred. A possible
solution to this challenge is to use PEGylated liposomes that
are lipid vesicles within which nucleic acids can be encapsulated
to avoid being filtered by the kidneys (Podesta and Kostarelos,
2009; McCaskill et al., 2013). To improve the mode of RNA
delivery, one of the formulations used was lipid nanoparticle (Shi
et al., 2011; Asai and Oku, 2014). The lipid nanoparticle consists
of lipoplexes, which are cationic lipids that drive interaction
between cationic lipids and the negatively charged siRNAs. One
of the studies tested this delivery method in rodents and non-
human primates and found the siRNA delivery that targets a
hepatocyte mRNA (transthyretin) was effective at dose as low as
0.01 and 0.1mg/kg, respectively (Semple et al., 2010). The mRNA
levels were reduced to up to 30% after 48 h of administration.
Another similar strategy with a more potent delivery formula
called the lipidoid was devised, which contained lipids with
amino polar head groups and non-polar alkyl tails (Love et al.,
2010). This lipidoid, when administered in a similar fashion as
the earlier study, decreased the transthyretin mRNA levels by
70% making it more effective than the lipoplex. Such advanced
lipid-based delivery systems indicate that they will be useful
in delivering ASOs to specific tissues in humans in the near
future.
An alternative to ASOs is generating miRNA-binding RNA
transcripts to sequester and inhibit specific miRNAs that can
be expressed via viral vectors in cell lines, plants, or model
animals (Ebert et al., 2007; Loya et al., 2009; Ebert and Sharp,
2010; Todesco et al., 2010; Fabbri et al., 2011). The first known
miRNA decoy consisted of an adenoviral vector with miRNA-
133 sites inserted in 3′UTR of GFP reporter gene under a
RNA polymerase II promoter (Care et al., 2007). There are two
commonly known miRNA decoys: miRZips and tough decoy
RNAs (TuD RNAs), which are transcribed by RNA polymerase
III (H1 or U6) (Haraguchi et al., 2009). miRZips are transcribed
by RNA polymerase III H1 promoter and express a single miRNA
decoy hairpin of which one strand is perfectly complementary
to the mature miRNA. This blocks or “zips” the function of
mature miRNA and hence the name miRZip. The TuDs are
also transcribed by RNA polymerase III. It consists of a 60 bp
long hairpin-shaped RNA which carries an internal loop that
can be exposed to two miRNA binding sites with a central bulge
(Androsavich and Chau, 2014). Such structural conformation
helps in bypassing Ago2 mediated cleavage and RISC mediated
destabilization eventually preventing its inactivation. This type
of decoy provides longer-term inhibition of miRNAs than the
miRZips or antisense RNA oligonucleotides. On the contrary,
sponge miRNA inhibitors are RNA polymerase III transcribed
non-structural RNA that harbors 4–12 consecutive miRNA
binding sites with central bulges that can be stable integrated
into the genome. Such sponges can be designed to be drug
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FIGURE 1 | (A) Antisense oligonucleotides (ASOs) relieve the
post-translational repression of target gene transcripts through their high
affinity binding to the microRNA induced silencing complex (miRISC).
Many ASOs are fully complementary to their miRNAs and will lead to
their degradation. (B) MicroRNA sponges utilize a reporter construct
with a 3′UTR containing multiple miRNA binding sites. These binding
sequences act as decoys and can sequester a large number or
miRISCs.
(tetracycline) inducible or can be under a tissue specific promoter
(Faghihi et al., 2010; Stenvang et al., 2012; Cheng et al., 2013;
Gebert et al., 2014). Such TuDs and sponges have been designed
and shown to effectively inhibit expression of miR-21 and let-7
(Xie et al., 2012). Further advancement in the field would be to
design such miRNA decoys that could inhibit specific miRNAs at
a particular developmental stage or a specific tissue in an animal
model system.
In addition to the mentioned “decoy” transcripts that compete
with miRNAs and block their function, miRNA replacement
therapy can be another approach to reintroduce missing
miRNA/s. For instance, let-7 levels were found to be low in
primary ovarian tumors and breast cell derived cancer stem cells
indicating its role as tumor suppressor in certain cancers (Yu
et al., 2007; Liu et al., 2013). Another commonly decreased level
miRNA found in various cancers is miR-34 (Cheng et al., 2014;
Okada et al., 2014). p53 is deleted in many cancer types and
p53 promotes transcription of miR-34, hence its low expression.
miR-34 also becomes an important tumor suppressor in many
sarcoma types. For instance, miR-34 levels inversely correlate
with poor patient survival outcomes indicating its potential
role as a diagnostic marker in Ewing sarcoma (Marino et al.,
2014). Re-introduction or replacement of such tumor suppressor
miRNAs can be applied as targeted therapy or adjuvant therapy to
the existing chemotherapy. Direct delivery of miRNAs or a viral
vector encoding short hairpin RNAs that eventually are processed
in mature miRNAs can be used to achieve the replenishment
of the missing miRNAs (Kota et al., 2009; Bader et al., 2010).
Multiple doses of miRNA with an optimal delivery method
should be able to correct the miRNA imbalance in a cell type.
Use of viral vectors can aid in better delivery, stability, and
assessment of the miRNA/s being added to a cell or tissue type.
In fact, miR-34 replacement therapy has shown promise against
cancer cell survival, stemness, metastasis, and chemoresistance
in various cancer cell types and animal models and is under
Phase I clinical trial undertaken by MiRNA Therapeutics (Bader,
2012). Alternatively, viral vectors can be used to deliver specific
gene target sequences to inhibit miRNAs in a specific organ,
while restoring the function in the rest of the body (Santulli
et al., 2014). For instance, adenoviral vector delivery of miR-126-
3p target sequences at the 3′ end of exogenous p27 selectively
protects endothelial cells from p27 overexpression and also
allows for complete restoration of endothelial cells (Santulli
et al., 2014). However, such proof-of-concept need to be shown
in cancer studies, where only the miRNA levels in tumors
is affected without disrupting the miRNAs in the adjacent
organs.
Conclusion
We believe that understanding the miRNA-directed gene
regulation will help us improve traditional gene therapy
approaches. The reason is that a single miRNA has the ability to
affect regulation of multiple genes and signaling pathways, and
strategies to target such miRNAs can cease production of such
deregulated genes. The anti-miRNAs and miRNA replacement
therapeutic approaches unveil the importance and need for
correction of the deregulatedmiRNAs and understandmany new
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roles of individual miRNAs in various sarcoma types. Such a
strategy would help develop drugs that are highly sensitive to
multiple deregulated genes and will make better approval for the
clinical trials. Moreover, many of the sarcomas are important
pediatric cancers and such miRNA therapeutic approaches will
help in improving and enhancing the survival rates of the
pediatric patients. Nonetheless, efficient and targeted delivery,
stability, and safety of such drugs still remain challenging but with
the advancement of the miRNA field we believe that technologies
will be developed to allow discovery and rapid development of
effective miRNA therapeutics.
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